- Home
- GPRE vs YDES Comparison
GPRE vs YDES Comparison
Compare GPRE & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPRE | YDES |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.2M | 894.2M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | GPRE | YDES |
|---|---|---|
| Price | $13.65 | $8.88 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $10.61 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 23.2K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,091,680,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.14 | $7.90 |
| 52 Week High | $15.64 | $25.00 |
Technical Indicators
Market Signals| Indicator | GPRE | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 37.49 |
| Support Level | $9.25 | $8.19 |
| Resistance Level | $15.64 | $13.19 |
| Average True Range (ATR) | 0.73 | 0.77 |
| MACD | -0.10 | -0.07 |
| Stochastic Oscillator | 21.03 | 17.11 |
Price Performance
Historical ComparisonAbout GPRE Green Plains Inc.
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
About YDES YD Bio Limited Ordinary Shares
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.